SynthesisPediatric rheumatology online journal2022
Similarities and differences between MIS-C and KD: a systematic review and meta-analysis.
Synthesis in Pediatric rheumatology online journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Comparative Analysis of Routine Blood Laboratory Tests in Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Among White and Black Children.Pediatric cardiology · 2026Article
- Comparative study of post- COVID-19 Kawasaki disease and multisystem inflammatory syndrome cases at Alexandria University Children's Hospital.BMC pediatrics · 2026Article
- Bacillus Calmette-Guérin scar reactivation (BCGitis) in Kawasaki disease: a scoping review.European journal of pediatrics · 2026Article
- Predicting recalcitrant hyperinflammatory disease course in children with Kawasaki disease and MIS-C.Pediatric rheumatology online journal · 2026Article
- [Multisystem inflammatory syndrome in a young infant with lymphocytosis and reactive thrombocytosis post COVID-19: Case report].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Comparison of Immunomodulatory Therapies for Cardiovascular Clinical and Inflammatory Markers Outcomes in Mild to Moderately Ill Hospitalized Multisystem Inflammatory Syndrome in Children Patients.Journal of cardiovascular development and disease · 2025Article
- Impact of COVID-19 infection on Kawasaki disease and immune status in children.Scientific reports · 2025Article
- Observational
- An Update on Multi-System Inflammatory Syndrome in Children.Current rheumatology reports · 2025Review
- Investigating the Role of Gut Microbiota in Pediatric Patients with Severe COVID-19 or MIS-C.Microorganisms · 2025Article
- Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.Frontiers in immunology · 2025Review
- Case Report: Long-term follow-up of multiple giant coronary artery aneurysm associated with multisystem inflammatory syndrome in children.Frontiers in pediatrics · 2025Article
- Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Pediatric cardiology · 2025Article
- Clinical Significance of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Pediatric Patients: Insights into Their Utility in the Presence or Absence of Pre-Existing Heart Conditions.International journal of molecular sciences · 2024Review
- Should we be afraid of long-term cardiac consequences in children with multisystem inflammatory syndrome? Experience from subsequent waves of COVID-19.European journal of pediatrics · 2024Article
- Longitudinal Cardiac Evaluation of Children with Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 by Conventional and Speckle-Tracking Echocardiography.Pediatric cardiology · 2024Article
- New insight into the intravenous immunoglobulin treatment in Multisystem Inflammatory Syndrome in children and adults.Italian journal of pediatrics · 2024Review
- Long-term outcomes and immune profiling in children with multisystem inflammatory syndrome (MIS-C).Acta bio-medica : Atenei Parmensis · 2023Article
- Unusual Manifestations of Kawasaki Disease in the COVID Era: A Case Series and Review of the Literature.Cureus · 2023Article
- Sex differences in coronavirus disease 2019 myocarditis.Current opinion in physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMultisystem inflammatory syndrome in children (MIS-C) is a new syndrome with some clinical manifestations similar to Kawasaki disease (KD), which is difficult to distinguish.
objectiveThe study aimed to characterize the demographic characteristics, clinical characteristics, laboratory features, cardiac complications, and treatment of MIS-C compared with KD. STUDY
designStudies were selected by searching the PubMed, EMBASE and so on before February 28, 2022. Statistical analyses were performed using Review Manager 5.4 software and STATA 14.0.
resultsFourteen studies with 2928 participants were included. MIS-C patients tended to be older and there was no significant difference in the sex ratio. In terms of clinical characteristics, MIS-C patients were more frequently represented with respiratory, gastrointestinal symptoms and shock. At the same time, they had a lower incidence of conjunctivitis than KD patients. MIS-C patients had lower lymphocyte counts, platelet (PLT) counts, erythrocyte sedimentation rates (ESRs), alanine transaminase (ALT), and albumin levels and had higher levels of aspartate transaminase (AST), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), troponin, C-reactive protein (CRP), D-dimer, fibrinogen, ferritin, and creatinine. MIS-C patients had a higher incidence of left ventricle (LV) dysfunction, valvular regurgitation, pericardial effusion, myocarditis, and pericarditis. The incidence of coronary artery lesion (CAL) was lower in MIS-C patients [OR (95% CI): 0.52 (0.29, 0.93), p =0.03], while it was similar in the acute period. MIS-C patients had higher utilization of glucocorticoids (GCs) and lower utilization of intravenous immune globulin (IVIG).
conclusionsThere were specific differences between MIS-C and KD, which might assist clinicians with the accurate recognition of MIS-C and further mechanistic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.